SCHEMBL651957

SCHEMBL651957

O=C1N/C(=N/Cc2ccccc2Cl)S/C1=C\c1cnc(NC(=O)C2CC2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 3/20 0.39
POLB P06746 2/20 0.39
PKM P14618 1/20 0.39
PTPN1 P18031 2/20 0.39
GSK3B P49841 3/20 0.39
ALOX12 P18054 1/20 0.39
LCK P06239 2/20 0.38
MAPK13 O15264 1/20 0.38
EGFR P00533 1/20 0.38
FYN P06241 1/20 0.38
HCK P08631 1/20 0.38
SRC P12931 1/20 0.38
JAK3 P52333 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648559 0.93 SMN1; SMN2 (0.42) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL650973 0.91 LMNA (0.39) LMNARAB9ASMN1; SMN2PKMPTPN1
SCHEMBL649936 0.90 MEN1 (0.43) LMNAHPGDPOLBPKMPTPN1
SCHEMBL649937 0.90 MEN1 (0.43) LMNAHPGDPOLBPKMPTPN1
SCHEMBL10176414 0.88 HPGD (0.53) HPGDPOLBPKMPTPN1GSK3B
SCHEMBL651064 0.86 PIM1 (0.47) LMNANPC1RAB9AHPGDPOLB
SCHEMBL651311 0.84 PTPN1 (0.41) SMN1; SMN2HPGDPOLBPKMPTPN1
SCHEMBL651355 0.82 PTPN1 (0.46) LMNAHPGDPOLBPKMPTPN1
SCHEMBL648806 0.81 HPGD (0.45) HPGDPOLBPKMPTPN1GSK3B
SCHEMBL648807 0.81 HPGD (0.45) HPGDPOLBPKMPTPN1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 LMNA 3772/4885NPC1 1074/4885RAB9A 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.